Holen Sie sich die Stockscreener-App
6.66
8.85%
0.56
Schlusskurs vom Vortag:
$6.10
Offen:
$6.21
24-Stunden-Volumen:
71,451
Relative Volume:
0.25
Marktkapitalisierung:
$414.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-76.41M
KGV:
-3.4688
EPS:
-1.92
Netto-Cashflow:
$-64.56M
1W Leistung:
+13.31%
1M Leistung:
+21.39%
6M Leistung:
-25.98%
1J Leistung:
-11.11%
1-Tages-Spanne:
$6.05
$6.73
1-Wochen-Bereich:
$5.80
$6.73
52-Wochen-Spanne:
$4.345
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Firmenname
Aura Biosciences Inc
Sektor
Branche
Telefon
(617)500-8864
Adresse
80 GUEST STREET, BOSTON
Vergleichen Sie AURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.68 | 377.61M | 0 | -76.41M | -64.56M | -1.92 |
|
ONC
Beone Medicines Ltd Adr
|
257.40 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.73 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2699 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.57 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
494.61 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-07-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2022-07-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Aktie (AURA) Neueste Nachrichten
BNP Paribas Financial Markets Invests $50,000 in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
15,427 Shares in Aura Biosciences, Inc. (NASDAQ:AURA) Acquired by ProShare Advisors LLC - Defense World
Ameriprise Financial Inc. Has $704,000 Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Learn to Evaluate (AURA) using the Charts - news.stocktradersdaily.com
Brokers Set Expectations for AURA Q2 Earnings - Defense World
Deutsche Bank AG Buys 15,951 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of “Buy” from Analysts - Defense World
Equities Analysts Offer Predictions for AURA FY2028 Earnings - Defense World
Aura Biosciences (NASDAQ:AURA) Raised to Buy at HC Wainwright - Defense World
H.C. Wainwright sets $22 target for Aura Biosciences stock By Investing.com - Investing.com Canada
Aura Biosciences (AURA) Receives 'Buy' Rating from HC Wainwright & Co. | AURA Stock News - GuruFocus
H.C. Wainwright sets $22 target for Aura Biosciences stock - Investing.com
Aura Biosciences assumed with a Buy at H.C. Wainwright - TipRanks
AURA: Analyst Initiates Buy Rating with $22 Price Target | AURA Stock News - GuruFocus
Innovative Precision Oncology and Promising Clinical Results Justify Buy Rating for Aura Biosciences Inc - TipRanks
Aura Biosciences (NASDAQ:AURA) Earns Market Outperform Rating from JMP Securities - Defense World
Northern Trust Corp Has $3.18 Million Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
JMP maintains $19 target on Aura Biosciences stock after FDA insights - Investing.com Canada
Strategic Positioning and Regulatory Advantage Bolster Aura Biosciences Inc’s Buy Rating - TipRanks
Anthony Gibney Buys 721% More Aura Biosciences Shares - simplywall.st
Long Term Trading Analysis for (AURA) - news.stocktradersdaily.com
Aura Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Major Stock Moves: Aura Biosciences Inc Sees Insider Buying Spree! - TipRanks
Promising Developments and Strategic Advancements Propel Aura Biosciences Inc’s Buy Rating - TipRanks
Aura Biosciences Advances in Cancer Therapy Trials - TipRanks
Aura Biosciences Raises $69.9 Million in Public Offering - TipRanks
Aura Biosciences announces public offering; shares down - MSN
Aura Biosciences: Strategic Advancements and Clinical Progress Drive Buy Rating - TipRanks
FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences Launches Public Offering Of Common Stock And Warrants - Nasdaq
Aura Biosciences announces common stock, warrant offering, no amount given - TipRanks
Aura Biosciences Prices $75 Million Offering of Shares, Warrants - marketscreener.com
Aura Biosciences sets terms for $75 million public offering By Investing.com - Investing.com India
Aura Biosciences sets terms for $75 million public offering - Investing.com Australia
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - GlobeNewswire
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - Benzinga
Aura Biosciences Secures $75M Funding: Major Push for Precision Cancer Treatment Development - Stock Titan
Aura Biosciences Launches Proposed Public Offering of Shares, Warrants - marketscreener.com
Aura Biosciences (AURA) Initiates Public Offering with Multiple Financial Managers | AURA Stock News - GuruFocus
Aura Biosciences Appoints New Chief Financial Officer - TipRanks
Aura Biosciences Announces Proposed Public Offering Of Common Stock And Warrants - marketscreener.com
Aura Biosciences, Inc. SEC 10-Q Report - TradingView
Aura Biosciences Enrolls First Patient in Phase 1b/2 Trial of Bel-sar for Non-Muscle-Invasive Bladder Cancer and Strengthens Leadership Team with New Appointment - Nasdaq
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants - GlobeNewswire
Major Cancer Therapy Developer Aura Biosciences Announces Strategic Public Offering with Top Wall Street Banks - Stock Titan
Aura Biosciences Hits Major Milestone in Bladder Cancer Trial, Reveals Strong Pipeline Progress - Stock Titan
Dimensional Fund Advisors LP Buys 73,062 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
(AURA) Trading Advice - news.stocktradersdaily.com
Barclays PLC Grows Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Analysts Set Aura Biosciences, Inc. (NASDAQ:AURA) Price Target at $22.75 - Defense World
Finanzdaten der Aura Biosciences Inc-Aktie (AURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aura Biosciences Inc-Aktie (AURA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Johnson David Michael | Director |
May 16 '25 |
Buy |
4.90 |
20,000 |
98,000 |
166,167 |
| Gibney Anthony S | See Remarks |
May 16 '25 |
Buy |
4.90 |
50,000 |
245,000 |
58,452 |
| Gibney Anthony S | See Remarks |
May 16 '25 |
Sale |
5.15 |
1,519 |
7,823 |
56,933 |
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):